Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease

World Journal of Gastroenterology

Volumn 22, Issue 41, 2016, Pages 9039-9043

  Makri, Evangelia ^a   Cholongitas, Evangelos ^a   Tziomalos, Konstantinos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Dyslipidemia; Farnesoid X receptors; Fibrosis; Hepatocellular cancer; Insulin resistance; Nonalcoholic fatty liver disease; Obeticholic acid; Steatosis

Indexed keywords

OBETICHOLIC ACID; BIOLOGICAL MARKER; CELL RECEPTOR; CHENODEOXYCHOLIC ACID; FARNESOID X-ACTIVATED RECEPTOR;

DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; HUMAN; LIFESTYLE MODIFICATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DRUG EFFECTS; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; CHENODEOXYCHOLIC ACID; HUMANS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TREATMENT OUTCOME;

EID: 84995511380     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i41.9039     Document Type: Review

References (38)

1. Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol 2016; 22: 91-105 [PMID: 26997214 DOI:10.4103/1319-3767.178527].
2. Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials 2014; 9: 126-133 [PMID: 25514916].
3. Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol 2011; 26 Suppl 1: 163-172 [PMID: 21199528 DOI:10.1111/j.1440-1746.2010.06548.x].
4. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-Alcoholic fatty liver disease and non-Alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285 [PMID: 21623852 DOI:10.1111/j.1365-2036.2011.04724.x].
5. Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602 [PMID: 20014114 DOI:10.1002/hep.23314].
6. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to nonalcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 248-254 [PMID: 19032450 DOI:10.1111/j.1440-1746.2008.05640.x].
7. Bellentani S, Dalle Grave R, Suppini A, Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology 2008; 47: 746-754 [PMID: 18098321 DOI:10.1002/hep.22009].
8. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023 [PMID: 22488764 DOI:10.1002/hep.25762].
9. Musso G, Gambino R, Cassader M, Pagano G. A meta-Analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104 [PMID: 20578268 DOI:10.1002/hep.23623].
10. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013; 59: 859-871 [PMID: 23751754DOI:10.1016/j.jhep.2013.05.044].
11. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003; 38 Suppl 1: S38-S53 [PMID: 12591185].
12. Lee FY, Kast-Woelbern HR, Chang J, Luo G, Jones SA, Fishbein MC, Edwards PA. Alpha-crystallin is a target gene of the farnesoid X-Activated receptor in human livers. J Biol Chem 2005; 280: 31792-31800 [PMID: 16012168 DOI:10.1074/jbc.M503182200].
13. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pruzanski M, Morelli A, Pellicciari R. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 2005; 314: 584-595 [PMID: 15860571 DOI:10.1124/jpet.105.084905].
14. Mencarelli A, Renga B, Distrutti E, Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol 2009; 296: H272-H281 [PMID: 19028791 DOI:10.1152/ajpheart.01075.2008].
15. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ, Shan B. Identification of a nuclear receptor for bile acids. Science 1999; 284: 1362-1365 [PMID: 10334992].
16. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999; 3: 543-553 [PMID: 10360171].
17. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 2012; 17: 988-997 [PMID: 22652341 DOI:10.1016/j.drudis.2012.05.012].
18. Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med 2015; 3: 5 [PMID: 25705637 DOI:10.3978/j.issn.2305-5839.2014.12.06].
19. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-582.e1 [PMID: 23727264 DOI:10.1053/j.gastro.2013.05.042].
20. Vignozzi L, Morelli A, Filippi S, Comeglio P, Chavalmane AK, Marchetta M, Toce M, Yehiely-Cohen R, Vannelli GB, Adorini L, Maggi M. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J Sex Med 2011; 8: 57-77 [PMID: 20955313 DOI:10.1111/j.1743-6109.2010.02073.x].
21. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010; 51: 771-784 [PMID: 19783811 DOI:10.1194/jlr.M001602].
22. Varela-Rey M, Embade N, Ariz U, Lu SC, Mato JM, Martínez- Chantar ML. Non-Alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol 2009; 41: 969-976 [PMID: 19027869 DOI:10.1016/j.biocel.2008.10.027].
23. Mencarelli A, Renga B, Migliorati M, Cipriani S, Distrutti E, Santucci L, Fiorucci S. The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. J Immunol 2009; 183: 6657-6666 [PMID: 19880446 DOI:10.4049/jimmunol.0901347].
24. Wang XX, Jiang T, Shen Y, Adorini L, Pruzanski M, Gonzalez FJ, Scherzer P, Lewis L, Miyazaki-Anzai S, Levi M. The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol 2009; 297: F1587-F1596 [PMID: 19776172 DOI:10.1152/ajprenal.00404.2009].
25. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SW. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011; 60: 463-472 [PMID: 21242261 DOI:10.1136/gut.2010.212159].
26. Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J Immunol 2009; 183: 6251-6261 [PMID: 19864602 DOI:10.4049/jimmunol.0803978].
27. Kong B, Luyendyk JP, Tawfik O, Guo GL. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in lowdensity lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 2009; 328: 116-122 [PMID: 18948497 DOI:10.1124/jpet.108.144600].
28. Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008; 48: 1632-1643 [PMID: 18972444 DOI:10.1002/hep.22519].
29. Zhang Y, Ge X, Heemstra LA, Chen WD, Xu J, Smith JL, Ma H, Kasim N, Edwards PA, Novak CM. Loss of FXR protects against diet-induced obesity and accelerates liver carcinogenesis in ob/ob mice. Mol Endocrinol 2012; 26: 272-280 [PMID: 22261820 DOI:10.1210/me.2011-1157].
30. Zhang Y, Yin L, Anderson J, Ma H, Gonzalez FJ, Willson TM, Edwards PA. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. J Biol Chem 2010; 285: 3035-3043 [PMID: 19996107 DOI:10.1074/jbc.M109.083899].
31. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark JM, Tonascia J, Brunt EM, Kleiner DE, Doo E. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-Alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebocontrolled trial. Lancet 2015; 385: 956-965 [PMID: 25468160 DOI:10.1016/S0140-6736(14)61933-4].
32. Pencek R, Marmon T, Roth JD, Liberman A, Hooshmand-Rad R, Young MA. Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers. Diabetes Obes Metab 2016; 18: 936-940 [PMID: 27109453 DOI:10.1111/dom.12681].
33. Silveira MG, Lindor KD. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis. Expert Opin Pharmacother 2014; 15: 365-372 [PMID: 24382005 DOI:10.1517/14656566.2014.873404].
34. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685 [PMID: 20427778 DOI:10.1056/NEJMoa0907929].
35. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelias ED, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and efficacy of long-Term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis. Lancet 2010; 376: 1916-1922 [PMID: 21109302 DOI:10.1016/S0140-6736(10)61272-X].
36. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2012; (3): CD007176 [PMID: 22419320 DOI:10.1002/14651858.CD007176.pub2].
37. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi- Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 2005; 366: 1279-1289 [PMID: 16214598 DOI:10.1016/S0140-6736(05)67528-9].
38. Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: An updated meta-Analysis of randomized clinical trials. Bone 2014; 68: 115-123 [PMID: 25173606 DOI:10.1016/j.bone.2014.08.010.